Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12-16

AUTHORS

Vishal Vashistha, David I Quinn, Tanya B Dorff, Siamak Daneshmand

ABSTRACT

BackgroundAlthough Muscle Invasive Bladder Cancer (MIBC) is increasing in incidence, treatment has largely remained limited to radical cystectomy with or without cisplatin-based neoadjuvant and/or adjuvant chemotherapy. We reviewed the current and recent clinical trials evaluating perioperative chemotherapy, targeted therapy, and novel therapeutic regimens for MIBC patients undergoing radical cystectomy.MethodsAn overview of perioperative MIBC management was conducted initially using MEDLINE. The Clinical Trials Registry and MEDLINE were further searched specifically for perioperative MIBC chemotherapy, targeted therapy, and other novel therapeutic approaches. Trials involving non-perioperative management, operative management other than radical cystectomy, multiple tumors, or purely superficial or metastatic disease were excluded from selection. These criteria were not specifically fulfilled for mTOR inhibitor and immune therapy trials. Only phase III chemotherapy and phase II targeted therapy trials found in the Clinical Trials Registry were selected. MEDLINE searches of specific treatments were limited to January 2009 to January 2014 whereas the Clinical Trials Registry search had no timeline. Systematic MEDLINE searches had no phase restrictions. Trials known by the authors to fulfill search criteria but were not found via searches were also selected.ResultsTwenty-five trials were selected from the Clinical Trials Registry including 7 phase III chemotherapy trials, 11 Phase II targeted therapy trials, 3 immune therapy trials, 1 mammalian target of rapamycin (mTOR) inhibitor trial, and 3 gene and vaccine therapy trials. Nine trials have been completed and 5 have been terminated early or withdrawn. Nine trials have data available when individually searched using MEDLINE and/or Google. Systematic searches of MEDLINE separately found 12 trials in the past 5 years. Two phase III chemotherapy trials were selected based on knowledge by the authors. No phase III trials of targeted therapy have been registered or published.ConclusionsNew trials are currently being conducted that may revolutionize MIBC treatment preceding or following cystectomy. Head-to-head phase III trials of perioperative chemotherapy and further phase II and phase III trials of targeted therapy and other therapeutic approaches are necessary before the current cisplatin-based perioperative chemotherapy paradigm is altered. More... »

PAGES

966

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-14-966

DOI

http://dx.doi.org/10.1186/1471-2407-14-966

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036811245

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25515347


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cancer Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase II as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cystectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscle, Smooth", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Invasiveness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Perioperative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vashistha", 
        "givenName": "Vishal", 
        "id": "sg:person.01130463257.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130463257.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "Tanya B", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Abe, Suite 7416, 90089, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Urology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Abe, Suite 7416, 90089, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daneshmand", 
        "givenName": "Siamak", 
        "id": "sg:person.01356212442.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356212442.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10147-012-0447-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041616619", 
          "https://doi.org/10.1007/s10147-012-0447-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature12965", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032218108", 
          "https://doi.org/10.1038/nature12965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00345-009-0383-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008652471", 
          "https://doi.org/10.1007/s00345-009-0383-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0216-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048653555", 
          "https://doi.org/10.1007/s12032-012-0216-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12-16", 
    "datePublishedReg": "2014-12-16", 
    "description": "BackgroundAlthough Muscle Invasive Bladder Cancer (MIBC) is increasing in incidence, treatment has largely remained limited to radical cystectomy with or without cisplatin-based neoadjuvant and/or adjuvant chemotherapy. We reviewed the current and recent clinical trials evaluating perioperative chemotherapy, targeted therapy, and novel therapeutic regimens for MIBC patients undergoing radical cystectomy.MethodsAn overview of perioperative MIBC management was conducted initially using MEDLINE. The Clinical Trials Registry and MEDLINE were further searched specifically for perioperative MIBC chemotherapy, targeted therapy, and other novel therapeutic approaches. Trials involving non-perioperative management, operative management other than radical cystectomy, multiple tumors, or purely superficial or metastatic disease were excluded from selection. These criteria were not specifically fulfilled for mTOR inhibitor and immune therapy trials. Only phase III chemotherapy and phase II targeted therapy trials found in the Clinical Trials Registry were selected. MEDLINE searches of specific treatments were limited to January 2009 to January 2014 whereas the Clinical Trials Registry search had no timeline. Systematic MEDLINE searches had no phase restrictions. Trials known by the authors to fulfill search criteria but were not found via searches were also selected.ResultsTwenty-five trials were selected from the Clinical Trials Registry including 7 phase III chemotherapy trials, 11 Phase II targeted therapy trials, 3 immune therapy trials, 1 mammalian target of rapamycin (mTOR) inhibitor trial, and 3 gene and vaccine therapy trials. Nine trials have been completed and 5 have been terminated early or withdrawn. Nine trials have data available when individually searched using MEDLINE and/or Google. Systematic searches of MEDLINE separately found 12 trials in the past 5\u00a0years. Two phase III chemotherapy trials were selected based on knowledge by the authors. No phase III trials of targeted therapy have been registered or published.ConclusionsNew trials are currently being conducted that may revolutionize MIBC treatment preceding or following cystectomy. Head-to-head phase III trials of perioperative chemotherapy and further phase II and phase III trials of targeted therapy and other therapeutic approaches are necessary before the current cisplatin-based perioperative chemotherapy paradigm is altered.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2407-14-966", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "muscle-invasive bladder cancer", 
      "Clinical Trials Registry", 
      "phase III chemotherapy trials", 
      "phase III trials", 
      "invasive bladder cancer", 
      "recent clinical trials", 
      "radical cystectomy", 
      "Trials Registry", 
      "therapy trials", 
      "perioperative chemotherapy", 
      "chemotherapy trials", 
      "III trials", 
      "bladder cancer", 
      "clinical trials", 
      "MEDLINE search", 
      "therapeutic approaches", 
      "clinical trial registry searches", 
      "head phase III trials", 
      "phase II", 
      "trial registry searches", 
      "vaccine therapy trials", 
      "further phase II", 
      "perioperative systemic therapy", 
      "novel therapeutic regimens", 
      "systematic MEDLINE search", 
      "novel therapeutic approaches", 
      "adjuvant chemotherapy", 
      "MIBC treatment", 
      "MIBC patients", 
      "metastatic disease", 
      "registry search", 
      "systemic therapy", 
      "inhibitor trials", 
      "operative management", 
      "therapeutic regimens", 
      "multiple tumors", 
      "specific treatment", 
      "mTOR inhibitors", 
      "cystectomy", 
      "chemotherapy", 
      "systematic review", 
      "therapy", 
      "MEDLINE", 
      "methodsAn overview", 
      "mammalian target", 
      "trials", 
      "registry", 
      "systematic search", 
      "cancer", 
      "treatment", 
      "search criteria", 
      "regimens", 
      "patients", 
      "tumors", 
      "management", 
      "incidence", 
      "disease", 
      "criteria", 
      "inhibitors", 
      "search", 
      "review", 
      "years", 
      "head", 
      "target", 
      "genes", 
      "authors", 
      "restriction", 
      "data", 
      "timeline", 
      "knowledge", 
      "overview", 
      "approach", 
      "paradigm", 
      "phase restrictions", 
      "selection", 
      "Google"
    ], 
    "name": "Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review", 
    "pagination": "966", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036811245"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-14-966"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25515347"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-14-966", 
      "https://app.dimensions.ai/details/publication/pub.1036811245"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_650.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2407-14-966"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-966'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-966'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-966'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-966'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      21 PREDICATES      120 URIs      108 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-14-966 schema:about N16c3b3b2d4fc4d6e999e57e729192212
2 N184a8c0517ea4c60bb987d30ee5a6708
3 N2ad7561c37204dbe919bf9013b33920d
4 N3d50d68bd44d4fd9b0af54ab211fc27b
5 N3e8a6045df67403385069e3d91cd9d87
6 N410a651816a94e2e9f1470d685a1e5bb
7 N415074bd1db44a4bbf77ff7fd78b23ae
8 N4e31f5eaa10c4db5b5315e7360ec6930
9 N591107838b704a6b8f629da0a90b50f8
10 N5c0db563d98e4488a1070653c728c93a
11 N6bc967e161994816a8595bdc899c8682
12 N88d803d3d42d4625b93452fe64313375
13 Nc8b3203ec7f945e695e2597ad53eabf9
14 Ne10df7b372ec4830a14a570fa567a4e0
15 Nf96581fdae3b4800a63130f419029e90
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N32751a8fb3e8468f88648d5a7fcdc49e
19 schema:citation sg:pub.10.1007/s00345-009-0383-3
20 sg:pub.10.1007/s10147-012-0447-z
21 sg:pub.10.1007/s12032-012-0216-x
22 sg:pub.10.1038/nature12965
23 schema:datePublished 2014-12-16
24 schema:datePublishedReg 2014-12-16
25 schema:description BackgroundAlthough Muscle Invasive Bladder Cancer (MIBC) is increasing in incidence, treatment has largely remained limited to radical cystectomy with or without cisplatin-based neoadjuvant and/or adjuvant chemotherapy. We reviewed the current and recent clinical trials evaluating perioperative chemotherapy, targeted therapy, and novel therapeutic regimens for MIBC patients undergoing radical cystectomy.MethodsAn overview of perioperative MIBC management was conducted initially using MEDLINE. The Clinical Trials Registry and MEDLINE were further searched specifically for perioperative MIBC chemotherapy, targeted therapy, and other novel therapeutic approaches. Trials involving non-perioperative management, operative management other than radical cystectomy, multiple tumors, or purely superficial or metastatic disease were excluded from selection. These criteria were not specifically fulfilled for mTOR inhibitor and immune therapy trials. Only phase III chemotherapy and phase II targeted therapy trials found in the Clinical Trials Registry were selected. MEDLINE searches of specific treatments were limited to January 2009 to January 2014 whereas the Clinical Trials Registry search had no timeline. Systematic MEDLINE searches had no phase restrictions. Trials known by the authors to fulfill search criteria but were not found via searches were also selected.ResultsTwenty-five trials were selected from the Clinical Trials Registry including 7 phase III chemotherapy trials, 11 Phase II targeted therapy trials, 3 immune therapy trials, 1 mammalian target of rapamycin (mTOR) inhibitor trial, and 3 gene and vaccine therapy trials. Nine trials have been completed and 5 have been terminated early or withdrawn. Nine trials have data available when individually searched using MEDLINE and/or Google. Systematic searches of MEDLINE separately found 12 trials in the past 5 years. Two phase III chemotherapy trials were selected based on knowledge by the authors. No phase III trials of targeted therapy have been registered or published.ConclusionsNew trials are currently being conducted that may revolutionize MIBC treatment preceding or following cystectomy. Head-to-head phase III trials of perioperative chemotherapy and further phase II and phase III trials of targeted therapy and other therapeutic approaches are necessary before the current cisplatin-based perioperative chemotherapy paradigm is altered.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N84d458f3911143aaa7e5bbc861c2cead
29 Ne65fb36221e14884a591d7be7687d363
30 sg:journal.1024632
31 schema:keywords Clinical Trials Registry
32 Google
33 III trials
34 MEDLINE
35 MEDLINE search
36 MIBC patients
37 MIBC treatment
38 Trials Registry
39 adjuvant chemotherapy
40 approach
41 authors
42 bladder cancer
43 cancer
44 chemotherapy
45 chemotherapy trials
46 clinical trial registry searches
47 clinical trials
48 criteria
49 cystectomy
50 data
51 disease
52 further phase II
53 genes
54 head
55 head phase III trials
56 incidence
57 inhibitor trials
58 inhibitors
59 invasive bladder cancer
60 knowledge
61 mTOR inhibitors
62 mammalian target
63 management
64 metastatic disease
65 methodsAn overview
66 multiple tumors
67 muscle-invasive bladder cancer
68 novel therapeutic approaches
69 novel therapeutic regimens
70 operative management
71 overview
72 paradigm
73 patients
74 perioperative chemotherapy
75 perioperative systemic therapy
76 phase II
77 phase III chemotherapy trials
78 phase III trials
79 phase restrictions
80 radical cystectomy
81 recent clinical trials
82 regimens
83 registry
84 registry search
85 restriction
86 review
87 search
88 search criteria
89 selection
90 specific treatment
91 systematic MEDLINE search
92 systematic review
93 systematic search
94 systemic therapy
95 target
96 therapeutic approaches
97 therapeutic regimens
98 therapy
99 therapy trials
100 timeline
101 treatment
102 trial registry searches
103 trials
104 tumors
105 vaccine therapy trials
106 years
107 schema:name Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review
108 schema:pagination 966
109 schema:productId N38dbe8076ab24bfeb4566cca8b82ca87
110 N76a07367ff814a85a627d1768ff6c52e
111 Nbd661a6948ab41c48e8b8dbd4520bcd6
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036811245
113 https://doi.org/10.1186/1471-2407-14-966
114 schema:sdDatePublished 2022-10-01T06:40
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher Na55ca918c94d49ae99ab166a12136c4a
117 schema:url https://doi.org/10.1186/1471-2407-14-966
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N16c3b3b2d4fc4d6e999e57e729192212 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Clinical Trials, Phase III as Topic
123 rdf:type schema:DefinedTerm
124 N184a8c0517ea4c60bb987d30ee5a6708 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Antineoplastic Agents
126 rdf:type schema:DefinedTerm
127 N2ad7561c37204dbe919bf9013b33920d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Chemotherapy, Adjuvant
129 rdf:type schema:DefinedTerm
130 N32751a8fb3e8468f88648d5a7fcdc49e rdf:first sg:person.01130463257.43
131 rdf:rest N6d0703554caa40479c173ca3a036670c
132 N376c35fbd83d43ca9bfb4a3d4bc2b8c1 rdf:first sg:person.01007666002.23
133 rdf:rest N94525212a48647e8b9d37cd716a08f1f
134 N38dbe8076ab24bfeb4566cca8b82ca87 schema:name dimensions_id
135 schema:value pub.1036811245
136 rdf:type schema:PropertyValue
137 N3d50d68bd44d4fd9b0af54ab211fc27b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Muscle, Smooth
139 rdf:type schema:DefinedTerm
140 N3e8a6045df67403385069e3d91cd9d87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Clinical Trials, Phase II as Topic
142 rdf:type schema:DefinedTerm
143 N410a651816a94e2e9f1470d685a1e5bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Urinary Bladder Neoplasms
145 rdf:type schema:DefinedTerm
146 N415074bd1db44a4bbf77ff7fd78b23ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cancer Vaccines
148 rdf:type schema:DefinedTerm
149 N4e31f5eaa10c4db5b5315e7360ec6930 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Neoplasm Invasiveness
151 rdf:type schema:DefinedTerm
152 N591107838b704a6b8f629da0a90b50f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Perioperative Care
154 rdf:type schema:DefinedTerm
155 N5c0db563d98e4488a1070653c728c93a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Neoadjuvant Therapy
157 rdf:type schema:DefinedTerm
158 N6bc967e161994816a8595bdc899c8682 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cystectomy
160 rdf:type schema:DefinedTerm
161 N6d0703554caa40479c173ca3a036670c rdf:first sg:person.01013134010.15
162 rdf:rest N376c35fbd83d43ca9bfb4a3d4bc2b8c1
163 N76a07367ff814a85a627d1768ff6c52e schema:name pubmed_id
164 schema:value 25515347
165 rdf:type schema:PropertyValue
166 N84d458f3911143aaa7e5bbc861c2cead schema:volumeNumber 14
167 rdf:type schema:PublicationVolume
168 N88d803d3d42d4625b93452fe64313375 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Molecular Targeted Therapy
170 rdf:type schema:DefinedTerm
171 N94525212a48647e8b9d37cd716a08f1f rdf:first sg:person.01356212442.53
172 rdf:rest rdf:nil
173 Na55ca918c94d49ae99ab166a12136c4a schema:name Springer Nature - SN SciGraph project
174 rdf:type schema:Organization
175 Nbd661a6948ab41c48e8b8dbd4520bcd6 schema:name doi
176 schema:value 10.1186/1471-2407-14-966
177 rdf:type schema:PropertyValue
178 Nc8b3203ec7f945e695e2597ad53eabf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Genetic Therapy
180 rdf:type schema:DefinedTerm
181 Ne10df7b372ec4830a14a570fa567a4e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 Ne65fb36221e14884a591d7be7687d363 schema:issueNumber 1
185 rdf:type schema:PublicationIssue
186 Nf96581fdae3b4800a63130f419029e90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name TOR Serine-Threonine Kinases
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
193 schema:name Oncology and Carcinogenesis
194 rdf:type schema:DefinedTerm
195 sg:journal.1024632 schema:issn 1471-2407
196 schema:name BMC Cancer
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.42505.36
200 schema:familyName Dorff
201 schema:givenName Tanya B
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
203 rdf:type schema:Person
204 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
205 schema:familyName Quinn
206 schema:givenName David I
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
208 rdf:type schema:Person
209 sg:person.01130463257.43 schema:affiliation grid-institutes:grid.239578.2
210 schema:familyName Vashistha
211 schema:givenName Vishal
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130463257.43
213 rdf:type schema:Person
214 sg:person.01356212442.53 schema:affiliation grid-institutes:grid.42505.36
215 schema:familyName Daneshmand
216 schema:givenName Siamak
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356212442.53
218 rdf:type schema:Person
219 sg:pub.10.1007/s00345-009-0383-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008652471
220 https://doi.org/10.1007/s00345-009-0383-3
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/s10147-012-0447-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1041616619
223 https://doi.org/10.1007/s10147-012-0447-z
224 rdf:type schema:CreativeWork
225 sg:pub.10.1007/s12032-012-0216-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048653555
226 https://doi.org/10.1007/s12032-012-0216-x
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/nature12965 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032218108
229 https://doi.org/10.1038/nature12965
230 rdf:type schema:CreativeWork
231 grid-institutes:grid.239578.2 schema:alternateName Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
232 schema:name Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
233 rdf:type schema:Organization
234 grid-institutes:grid.42505.36 schema:alternateName Department of Urology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Abe, Suite 7416, 90089, Los Angeles, CA, USA
235 Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA
236 schema:name Department of Urology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Abe, Suite 7416, 90089, Los Angeles, CA, USA
237 Division of Oncology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...